SOURCE: BioVentrix

November 14, 2007 13:39 ET

New Cardiac Procedure Introduced to Interventional Cardiologists Holds Promise for Heart Failure Patients

SAN RAMON, CA--(Marketwire - November 14, 2007) - BioVentrix (the "Company") announced that its breakthrough product concept, Remote Ventricular Reduction (RVR), was unveiled last month at the world's largest gathering of Interventional Cardiologists, the Transcatheter Cardiovascular Therapeutics (TCT) conference, held in Washington, D.C. RVR is a product being developed to downsize the enlarged left ventricle in patients with heart failure. At the conference, results of initial RVR studies in sheep were presented. In these cases, the procedure improved the heart's pumping ability, decreased muscle wall tension and created a more normal-sized heart. Up until now, it has taken open heart surgery to achieve these results.

At a session titled "Interventional Heart Failure: Recent Developments and New Directions," Gary Gershony, MD, Interventional Cardiologist and one of the Company's medical advisors, told a large crowd of physicians and industry representatives that with initial application in animals, results are at par with published outcomes achieved by surgeons in humans. "Although this is early data," Gershony said, "the reductions in left ventricular volumes and improvement in ejection fraction are as good as has been reported in surgical series."

Almost 300,000 Americans die of heart failure each year, and there are 550,000 new diagnoses annually. Heart failure is the number one Medicare diagnosis, yet there is no cure.

Dr. Gershony compared the RVR approach to Left Ventricular Reconstruction, an 'open heart' operation performed by heart surgeons. Gershony outlined the development of the concept that allows the same reduction in heart size and wall stress, but utilizes a catheter. The Company's scientific team was able to reconstruct the dilated hearts in the animals using devices that fit through tubes no larger than a drinking straw.

In addition to making the hearts 30 percent to 40 percent smaller, the percentage of blood in the heart squeezed out with each beat, known as the "ejection fraction," was improved by 14 percent. "This will give a lot of fragile and debilitated patients access to the benefits of a procedure that may be too invasive for them to tolerate if only available surgically," said Kenneth Miller, President and CEO of BioVentrix. "Our aim is to make a difference where it will have the most impact," he continued. "If we can offer the procedure through this approach, we can normalize a patient's cardiac function... and, he can go home the next day."

About BioVentrix

BioVentrix is a private corporation based in San Ramon, California. Its mission is to improve and expand on the surgical treatment of heart failure by left ventricular reconstruction, primarily through the development of less invasive approaches, and ultimately, catheter-based procedures. BioVentrix's Scientific Advisory Board and associated physicians include some of the country's leading surgeons and cardiologists. For more information, please visit www.bioventrix.com.

Contact Information